2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
6
Not yet recruiting
2
Completed
2
Withdrawn
1
Unknown
1
Terminated
1
Approved for marketing
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Lung Diseases
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colonic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
1499
Cisplatin
1435
Paclitaxel
1340
Radiotherapy
1310
Carboplatin
1267
Gemcitabine
1226
Docetaxel
1133
Bevacizumab
1070
Fluorouracil
906
Doxorubicin
805
Dexamethasone
755
Rituximab
744
Capecitabine
735
Oxaliplatin
709
pembrolizumab
700
Etoposide
679
Irinotecan
639
Filgrastim
624
Cytarabine
587
Nivolumab
586
Leucovorin
583
Vincristine
517
Cetuximab
479
Prednisone
478
Bortezomib
474
Trastuzumab
468
Erlotinib Hydrochloride
467
Surveys and Questionnaires
460
Methotrexate
444
Lenalidomide
436
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts